Introduction: Patients with previously untreated (1L) diffuse large B-cell lymphoma (DLBCL) typically receive rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP); however, around 40% of these patients relapse. Complete response rates and long-term outcomes are worse for high-risk patients with International Prognostic Index (IPI) 3–5 or double-hit/triple-hit lymphoma, representing an underserved patient population requiring better curative options.